CASI Pharmaceuticals, Inc.
CASIDrugs in Pipeline
12
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
pemetrexed
Advanced Cancer
Sunitinib Malate
Metastatic Renal Cell Carcinoma
recombinant human Angiostatin protein
Carcinoma, Non-Small-Cell Lung
CID-103
Chronic Immune Thrombocytopenia
Panzem NCD
Recurrent Glioblastoma Multiforme
ENMD-2076
Ovarian Cancer
MKC-1
Ovarian Cancer
Panzem Nanocrystal Colloidal Dispersion (NCD)
Ovarian Cancer
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Carcinoid Tumor
2-methoxyestradiol
Relapsed Multiple Myeloma
Panzem Nanocrystal Colloidal Dispersion
Recurrent Glioblastoma Multiforme
Panzem® NCD
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pemetrexed | Phase 2 | Advanced Cancer | - | Patent 2036 |
Sunitinib Malate | Phase 2 | Metastatic Renal Cell Carcinoma | - | |
recombinant human Angiostatin protein | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
CID-103 | Phase 2 | Chronic Immune Thrombocytopenia | - | - |
Panzem NCD | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
ENMD-2076 | Phase 2 | Ovarian Cancer | - | - |
MKC-1 | Phase 2 | Ovarian Cancer | - | - |
Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | Ovarian Cancer | - | - |
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Phase 2 | Carcinoid Tumor | - | - |
2-methoxyestradiol | Phase 2 | Relapsed Multiple Myeloma | - | - |
Panzem Nanocrystal Colloidal Dispersion | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
Panzem® NCD | Phase 2 | Prostate Cancer | - | - |
Ovarian Cancer
3 drugs in this indication
Recurrent Glioblastoma Multiforme
2 drugs in this indication
Metastatic Renal Cell Carcinoma
1 drug in this indication
Chronic Immune Thrombocytopenia
1 drug in this indication
Advanced Cancer
1 drug in this indication
Relapsed Multiple Myeloma
1 drug in this indication
Prostate Cancer
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Carcinoid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CASI Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in CASI Pharmaceuticals, Inc.'s (CASI) pipeline across Phase 2. Its lead program is pemetrexed (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CASI Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CASI Pharmaceuticals, Inc. (CASI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CASI biotech catalysts?→
Add CASI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CASI Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.